Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This is a monocentric, single arm, prospective, open-label trial of a combination treatment
consisting of pembrolizumab and maraviroc in previously treated subjects who have refractory
microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Phase:
Phase 1
Details
Lead Sponsor:
University Hospital Heidelberg
Collaborators:
Institut für Klinisch-Onkologische Forschung, Krankenhaus Nordwest GmbH Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest